One-Step Conjugation Method for Site-Specific Antibody-Drug Conjugates through Reactive Cysteine-Engineered Antibodies

Bioconjugate Chemistry

Volumn 27, Issue 5, 2016, Pages 1324-1331

  Shinmi, Daisuke ^a   Taguchi, Eri ^a   Iwano, Junko ^a   Yamaguchi, Tsuyoshi ^a   Masuda, Kazuhiro ^a   Enokizono, Junichi ^a   Shiraishi, Yasuhisa ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADDITION REACTIONS; ANTIBODIES; CELL ENGINEERING; HYDROLYSIS; PLASMA STABILITY; SULFUR COMPOUNDS;

% REDUCTIONS; ANTIBODY-DRUG CONJUGATES; CHINESE HAMSTERS; CYSTEINE RESIDUES; LIGHT CHAIN; MALEIMIDES; OXIDIZATION; REACTIVE CYSTEINE; SITE-SPECIFIC; SPECIFIC CONJUGATIONS;

AMINO ACIDS;

ALBUMIN; ANION EXCHANGE RESIN; CYSTEINE; IMMUNOGLOBULIN G; SUCCINIMIDE; THIOL; TRASTUZUMAB; ANTIBODY CONJUGATE; THIOL DERIVATIVE;

ANIMAL CELL; ANION EXCHANGE; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; FEMALE; FERMENTATION; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; LIGHT CHAIN; MICHAEL ADDITION; MOLECULAR WEIGHT; NONHUMAN; ANIMAL; BINDING SITE; CHEMISTRY; ENZYME SPECIFICITY; GENETICS; HUMAN; MALE; MOUSE; PROTEIN ENGINEERING;

ANIMALS; BINDING SITES; CYSTEINE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; MALE; MICE; PROTEIN ENGINEERING; SUBSTRATE SPECIFICITY; SULFHYDRYL COMPOUNDS;

EID: 84971251113     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.6b00133     Document Type: Article

References (32)

1. Mullard, A. (2013) Maturing antibody-drug conjugate pipeline hits 30 Nat. Rev. Drug Discovery 12, 329-32 10.1038/nrd4009
2. Chari, R. V., Miller, M. L., and Widdison, W. C. (2014) Antibody-drug conjugates: an emerging concept in cancer therapy Angew. Chem., Int. Ed. 53, 3796-827 10.1002/anie.201307628
3. Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., and Zabinski, R. F. et al. 2004, Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10, 7063-70 10.1158/1078-0432.CCR-04-0789
4. Agarwal, P. and Bertozzi, C. R. (2015) Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development Bioconjugate Chem. 26, 176-92 10.1021/bc5004982
5. Voynov, V., Chennamsetty, N., Kayser, V., Wallny, H. J., Helk, B., and Trout, B. L. (2010) Design and application of antibody cysteine variants Bioconjugate Chem. 21, 385-92 10.1021/bc900509s
6. Junutula, J. R., Bhakta, S., Raab, H., Ervin, K. E., Eigenbrot, C., Vandlen, R., Scheller, R. H., and Lowman, H. B. (2008) Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs J. Immunol. Methods 332, 41-52 10.1016/j.jim.2007.12.011
7. Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., and Dennis, M. S. et al. 2008, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26, 925-32 10.1038/nbt.1480
8. Stimmel, J. B., Merrill, B. M., Kuyper, L. F., Moxham, C. P., Hutchins, J. T., Fling, M. E., and Kull, F. C., Jr. (2000) Site-specific conjugation on serine right-arrow cysteine variant monoclonal antibodies J. Biol. Chem. 275, 30445-50 10.1074/jbc.M001672200
9. Lyons, A., King, D. J., Owens, R. J., Yarranton, G. T., Millican, A., Whittle, N. R., and Adair, J. R. (1990) Site-specific attachment to recombinant antibodies via introduced surface cysteine residues Protein Eng., Des. Sel. 3, 703-8 10.1093/protein/3.8.703
10. Zhou, Q., Stefano, J. E., Manning, C., Kyazike, J., Chen, B., Gianolio, D. A., Park, A., Busch, M., Bird, J., and Zheng, X. et al. 2014, Site-specific antibody-drug conjugation through glycoengineering Bioconjugate Chem. 25, 510-20 10.1021/bc400505q
11. Li, X., Fang, T., and Boons, G. J. (2014) Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions Angew. Chem., Int. Ed. 53, 7179-82 10.1002/anie.201402606
12. Zimmerman, E. S., Heibeck, T. H., Gill, A., Li, X., Murray, C. J., Madlansacay, M. R., Tran, C., Uter, N. T., Yin, G., Rivers, P. J., and Yam, A. Y. et al. 2014, Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system Bioconjugate Chem. 25, 351-61 10.1021/bc400490z
13. Tian, F., Lu, Y., Manibusan, A., Sellers, A., Tran, H., Sun, Y., Phuong, T., Barnett, R., Hehli, B., and Song, F. et al. 2014, A general approach to site-specific antibody drug conjugates Proc. Natl. Acad. Sci. U. S. A. 111, 1766-71 10.1073/pnas.1321237111
14. Drake, P. M., Albers, A. E., Baker, J., Banas, S., Barfield, R. M., Bhat, A. S., de Hart, G. W., Garofalo, A. W., Holder, P., and Jones, L. C. et al. 2014, Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes Bioconjugate Chem. 25, 1331-41 10.1021/bc500189z
15. Dennler, P., Chiotellis, A., Fischer, E., Bregeon, D., Belmant, C., Gauthier, L., Lhospice, F., Romagne, F., and Schibli, R. (2014) Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates Bioconjugate Chem. 25, 569-78 10.1021/bc400574z
16. Shen, B. Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S. F., and Mai, E. et al. 2012, Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 30, 184-9 10.1038/nbt.2108
17. Shiraishi, Y., Muramoto, T., Nagatomo, K., Shinmi, D., Honma, E., Masuda, K., and Yamasaki, M. (2015) Identification of highly reactive cysteine residues at less exposed positions in the Fab constant region for site-specific conjugation Bioconjugate Chem. 26, 1032-40 10.1021/acs.bioconjchem.5b00080
18. Hamilton, G. S. (2015) Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids Biologicals 43, 318-32 10.1016/j.biologicals.2015.05.006
19. Bhakta, S., Raab, H., and Junutula, J. R. (2013) Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers. In Methods in Molecular Biology. Vol. 1045: Antibody-Drug Conjugtes (Ducry, L., Ed.) pp 189-204, Springer, New York.
20. Baldwin, A. D. and Kiick, K. L. (2011) Tunable degradation of maleimide-thiol adducts in reducing environments Bioconjugate Chem. 22, 1946-53 10.1021/bc200148v
21. Fontaine, S. D., Reid, R., Robinson, L., Ashley, G. W., and Santi, D. V. (2015) Long-term stabilization of maleimide-thiol conjugates Bioconjugate Chem. 26, 145-52 10.1021/bc5005262
22. Tumey, L. N., Charati, M., He, T., Sousa, E., Ma, D., Han, X., Clark, T., Casavant, J., Loganzo, F., and Barletta, F. et al. 2014, Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy Bioconjugate Chem. 25, 1871-80 10.1021/bc500357n
23. Lyon, R. P., Setter, J. R., Bovee, T. D., Doronina, S. O., Hunter, J. H., Anderson, M. E., Balasubramanian, C. L., Duniho, S. M., Leiske, C. I., Li, F., and Senter, P. D. (2014) Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates Nat. Biotechnol. 32, 1059-62 10.1038/nbt.2968
24. Jackson, D., Atkinson, J., Guevara, C. I., Zhang, C., Kery, V., Moon, S. J., Virata, C., Yang, P., Lowe, C., and Pinkstaff, J. et al. 2014, In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates PLoS One 9, e83865 10.1371/journal.pone.0083865
25. Behrens, C. R., Ha, E. H., Chinn, L. L., Bowers, S., Probst, G., Fitch-Bruhns, M., Monteon, J., Valdiosera, A., Bermudez, A., and Liao-Chan, S. et al. 2015, Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs Mol. Pharmaceutics 12, 3986-98 10.1021/acs.molpharmaceut.5b00432
26. Badescu, G., Bryant, P., Bird, M., Henseleit, K., Swierkosz, J., Parekh, V., Tommasi, R., Pawlisz, E., Jurlewicz, K., and Farys, M. et al. 2014, Bridging disulfides for stable and defined antibody drug conjugates Bioconjugate Chem. 25, 1124-36 10.1021/bc500148x
27. Sugio, S., Kashima, A., Mochizuki, S., Noda, M., and Kobayashi, K. (1999) Crystal structure of human serum albumin at 2.5 A resolution Protein Eng., Des. Sel. 12, 439-46 10.1093/protein/12.6.439
28. Turell, L., Radi, R., and Alvarez, B. (2013) The thiol pool in human plasma: the central contribution of albumin to redox processes Free Radical Biol. Med. 65, 244-53 10.1016/j.freeradbiomed.2013.05.050
29. Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., and Senter, P. D. (2008) Contribution of linker stability to the activities of anticancer immunoconjugates Bioconjugate Chem. 19, 759-65 10.1021/bc7004329
30. Patterson, J. T., Asano, S., Li, X., Rader, C., and Barbas, C. F., 3rd (2014) Improving the serum stability of site-specific antibody conjugates with sulfone linkers Bioconjugate Chem. 25, 1402-7 10.1021/bc500276m
31. Toda, N., Asano, S., and Barbas, C. F., 3rd (2013) Rapid, stable, chemoselective labeling of thiols with Julia-Kocienski-like reagents: a serum-stable alternative to maleimide-based protein conjugation Angew. Chem., Int. Ed. 52, 12592-6 10.1002/anie.201306241
32. Vinogradova, E. V., Zhang, C., Spokoyny, A. M., Pentelute, B. L., and Buchwald, S. L. (2015) Organometallic palladium reagents for cysteine bioconjugation Nature 526, 687-91 10.1038/nature15739